These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33025309)

  • 1. Dutch translation and linguistic validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™).
    Veldhuijzen E; Walraven I; Mitchell SA; Moore EY; McKown SM; Lauritzen M; Kim KJ; Belderbos JSA; Aaronson NK
    J Patient Rep Outcomes; 2020 Oct; 4(1):81. PubMed ID: 33025309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Linguistic validation of the simplified Chinese version of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Kkf C; Mitchell SA; Chan N; Ang E; Tam W; Kanesvaran R
    BMC Cancer; 2020 Nov; 20(1):1153. PubMed ID: 33243173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
    J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Arnold B; Mitchell SA; Lent L; Mendoza TR; Rogak LJ; Barragán NM; Willis G; Medina M; Lechner S; Penedo FJ; Harness JK; Basch EM;
    Support Care Cancer; 2016 Jul; 24(7):2843-51. PubMed ID: 26838022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linguistic Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean.
    Cho J; Yoon J; Kim Y; Oh D; Kim SJ; Ahn J; Suh GY; Nam SJ; Mitchell SA
    J Glob Oncol; 2019 Mar; 5():1-10. PubMed ID: 30917069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reliability and Validity of the Korean Language Version of the U.S. National Cancer Institute's Patient-Reported Outcomes Common Terminology Criteria for Adverse Events.
    Yoon J; Sim SH; Kang D; Han G; Kim Y; Ahn J; Oh D; Lee ES; Kong SY; Cho J; Mitchell SA
    J Pain Symptom Manage; 2020 May; 59(5):1082-1088.e6. PubMed ID: 32044423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®).
    Caminiti C; Bryce J; Riva S; Ng D; Diodati F; Iezzi E; Sparavigna L; Novello S; Porta C; Del Mastro L; Procopio G; Cinieri S; Falzetta A; Calabrò F; Lorusso V; Cogoni AA; Tortora G; Maruzzo M; Passalacqua R; Cognetti F; Adamo V; Capelletto E; Ferrari A; Bagnalasta M; Bassi M; Nicelli A; De Persis D; D'Acunti A; Iannelli Patient E; Perrone F; Mitchell SA
    Tumori; 2023 Jun; 109(3):324-334. PubMed ID: 35674125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Miyaji T; Iioka Y; Kuroda Y; Yamamoto D; Iwase S; Goto Y; Tsuboi M; Odagiri H; Tsubota Y; Kawaguchi T; Sakata N; Basch E; Yamaguchi T
    J Patient Rep Outcomes; 2017; 1(1):8. PubMed ID: 29757296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Hay JL; Atkinson TM; Reeve BB; Mitchell SA; Mendoza TR; Willis G; Minasian LM; Clauser SB; Denicoff A; O'Mara A; Chen A; Bennett AV; Paul DB; Gagne J; Rogak L; Sit L; Viswanath V; Schrag D; Basch E;
    Qual Life Res; 2014 Feb; 23(1):257-69. PubMed ID: 23868457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).
    Hagelstein V; Ortland I; Wilmer A; Mitchell SA; Jaehde U
    Ann Oncol; 2016 Dec; 27(12):2294-2299. PubMed ID: 27681863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Basch E; Reeve BB; Mitchell SA; Clauser SB; Minasian LM; Dueck AC; Mendoza TR; Hay J; Atkinson TM; Abernethy AP; Bruner DW; Cleeland CS; Sloan JA; Chilukuri R; Baumgartner P; Denicoff A; St Germain D; O'Mara AM; Chen A; Kelaghan J; Bennett AV; Sit L; Rogak L; Barz A; Paul DB; Schrag D
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation Into Simplified Chinese and Cultural Validation of the Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events Using Cognitive Interviewing.
    Shen N; Ruan H; Sun J; Li Y; He M; Yuan C; Chang L
    Cancer Nurs; 2023 Jan-Feb 01; 46(1):E31-E40. PubMed ID: 35583994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Chung AE; Shoenbill K; Mitchell SA; Dueck AC; Schrag D; Bruner DW; Minasian LM; St Germain D; O'Mara AM; Baumgartner P; Rogak LJ; Abernethy AP; Griffin AC; Basch EM
    J Am Med Inform Assoc; 2019 Apr; 26(4):276-285. PubMed ID: 30840079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
    JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.
    Reeve BB; McFatrich M; Pinheiro LC; Freyer DR; Basch EM; Baker JN; Withycombe JS; Sung L; Mack JW; Waldron MK; Mowbray C; Palma D; Hinds PS
    J Pain Symptom Manage; 2017 Apr; 53(4):759-766. PubMed ID: 28062347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
    Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation.
    Kirsch M; Mitchell SA; Dobbels F; Stussi G; Basch E; Halter JP; De Geest S
    Eur J Oncol Nurs; 2015 Feb; 19(1):66-74. PubMed ID: 25190633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stakeholder perspectives on implementing the National Cancer Institute's patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bruner DW; Hanisch LJ; Reeve BB; Trotti AM; Schrag D; Sit L; Mendoza TR; Minasian L; O'Mara A; Denicoff AM; Rowland JH; Montello M; Geoghegan C; Abernethy AP; Clauser SB; Castro K; Mitchell SA; Burke L; Trentacosti AM; Basch EM
    Transl Behav Med; 2011 Mar; 1(1):110-22. PubMed ID: 24073038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LUTS patient reported outcomes tool: linguistic validation in 10 European languages.
    Brandt BA; Angün Ç; Coyne KS; Doshi S; Bavendam T; Kopp ZS
    Neurourol Urodyn; 2013 Jan; 32(1):75-81. PubMed ID: 22674460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
    Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
    J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.